OpenProtein.AI is making advanced AI-driven protein design tools available to biologists through a user-friendly, no-code platform. The company is facilitating faster drug development by allowing scientists to design, predict, and optimize proteins without requiring machine learning expertise.
Helical, a biotech firm focusing on AI-driven pharmaceutical research, has raised $10 million in a seed funding round led by Redalpine. The company’s virtual AI lab aims to streamline drug discovery by integrating computational predictions with biological validation. The funds will support deeper collaborations with pharmaceutical companies and further platform development.
Life sciences companies face significant challenges in scaling generative AI due to insufficient data maturity and fragmented data sources. Experts highlight the need for robust data infrastructures, standardized evaluation benchmarks, and organizational alignment to unlock the full potential of AI in R&D workflows.
Recent advances show artificial intelligence reaching greater maturity in scientific research, with several new frameworks integrating AI more deeply into discovery workflows. Key projects include Penn State's ZENN model for heterogeneous data, a multimodal seismic foundation model led by Pacific Northwest National Laboratory, and the Allen Institute’s automated hypothesis generation system. These developments underscore AI’s shift from experimentation to practical, supportive roles in diverse scientific domains.
Amid rising regulatory concerns and the strategic importance of AI, Europe is actively cultivating its digital independence by developing alternatives to US Big Tech across infrastructure, AI, productivity tools, and consumer platforms. A growing ecosystem of European companies and open-source initiatives signals a shift toward sovereignty, privacy, and alignment with local values.
Stay informed with curated insights delivered weekly to your inbox.